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To determine the proportion of patients with COVID‑19 who were readmitted to the hospital and the 
most common causes and the factors associated with readmission. Multicenter nationwide cohort 
study in Spain. Patients included in the study were admitted to 147 hospitals from March 1 to April 
30, 2020. Readmission was defined as a new hospital admission during the 30 days after discharge. 
Emergency department visits after discharge were not considered readmission. During the study 
period 8392 patients were admitted to hospitals participating in the SEMI‑COVID‑19 network. 298 
patients (4.2%) out of 7137 patients were readmitted after being discharged. 1541 (17.7%) died 
during the index admission and 35 died during hospital readmission (11.7%, p = 0.007). The median 
time from discharge to readmission was 7 days (IQR 3–15 days). The most frequent causes of hospital 
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readmission were worsening of previous pneumonia (54%), bacterial infection (13%), venous 
thromboembolism (5%), and heart failure (5%). Age [odds ratio (OR): 1.02; 95% confident interval 
(95% CI): 1.01–1.03], age‑adjusted Charlson comorbidity index score (OR: 1.13; 95% CI: 1.06–1.21), 
chronic obstructive pulmonary disease (OR: 1.84; 95% CI: 1.26–2.69), asthma (OR: 1.52; 95% CI: 
1.04–2.22), hemoglobin level at admission (OR: 0.92; 95% CI: 0.86–0.99), ground‑glass opacification 
at admission (OR: 0.86; 95% CI:0.76–0.98) and glucocorticoid treatment (OR: 1.29; 95% CI: 1.00–1.66) 
were independently associated with hospital readmission. The rate of readmission after hospital 
discharge for COVID‑19 was low. Advanced age and comorbidity were associated with increased risk of 
readmission.
The novel coronavirus disease 2019 (COVID-19) pandemic has dramatically impacted many hospitals around 
the world. For several weeks, the demand for hospital beds in Spain surpassed the capacity to admit patients, 
hindering the ability to treat other serious illnesses such as neoplasms or cardiovascular  disease1–3. After the high-
est incidence of this infection during the months of March and April 2020, outbreaks of varying magnitudes are 
being observed in different regions throughout the world that could eventually compromise hospitals’ capacity 
 again4. Therefore, improving knowledge on the course of the disease could contribute to the appropriate use of 
the health resources available within the epidemiological framework.
The aforementioned potential shortage of hospital beds and the lack of firmly established discharge recom-
mendations could result in the hasty, risky discharge of admitted patients. Conversely, physicians may act in an 
overly cautious manner, unnecessarily prolonging hospital stays. Although the evolution of microbiological tests 
after the acute phase of the disease [polymerase chain reaction (PCR) of nasal exudate)] has been the subject of 
several studies, the clinical characteristics of patients at increased risk of readmission have been analyzed in a 
limited number of  studies5–10. Increased knowledge of the magnitude and characteristics of this issue could help 
in decision-making related to the initial hospital stay, time of discharge, and clinical follow-up after discharge.
The SEMI-COVID-19 Network has arisen as an initiative of the Spanish Society of Internal Medicine (SEMI, 
for its initials in Spanish) to improve the management of COVID-19. The main objective of the registry is to 
generate, in a short period of time, a large, multicenter cohort with detailed information on the epidemiol-
ogy, clinical progress, and treatment received by  patients11. Using this information, we aimed to determine the 
proportion of COVID-19 patients who were readmitted after discharge, the causes of readmission, and factors 
associated with this poor outcome.
Methods
Study design. This is an observational study base on the SEMI-COVID-19 Registry, which is a retrospective 
cohort comprising consecutive patients admitted in 147 hospitals in Spain from March 1, 2020 discharged with 
confirmed COVID-19 disease. The aim of the study was to analyze the clinical characteristics of patients with 
COVID-19 who were readmitted to the hospital during the first 30 days after being discharged. Patients included 
in the SEMI-COVID-19 Registry from March 1, 2020 to April 30, 2020 were included in this study, representing 
approximately 10% of the patients admitted in Spain during this time  period1. Comparative group was consti-
tuted by patients who were discharged alive from the primary admission and were not readmitted during the 
30 days following discharge. Patients who were attended in the emergency department after hospital discharge 
but that were not admitted, were not considered as readmitted patient.
Study population and participants. All consecutive patients discharged after hospital admission with 
confirmed SARS-CoV-2 infection were eligible for inclusion in the SEMI-COVID-19  Registry11. COVID-19 was 
confirmed by a positive result on real-time polymerase chain reaction (RT-PCR) testing of a nasopharyngeal or 
sputum sample. Patients were treated at their attending physician’s discretion, according to local protocols and 
clinical judgement. Patients included in open-label clinical trials could be included in the registry, provided all 
information about treatment was available.
Data collection. Data were entered into the database by retrospective review of medical records by resident 
or staff physicians of the internal medicine departments of the participating hospitals. An online electronic data 
capture system was developed, which includes a database manager along with procedures for the verification of 
data and contrasting of information against the original medical record in order to ensure the best possible qual-
ity of data collection. Patient identifiable data were dissociated and pseudonymized. Collected data and included 
epidemiological data, RT-PCR and serology data, medical and medication history, symptoms and physical 
examination findings at admission, laboratory and diagnostic imaging tests, treatment, complications during 
the hospitalization, and hospital readmission. Obesity was defined as a body mass index greater than 30 kg/m2. 
Acute cardiac injury was defined as the detection of acute myocardial infarction, heart failure, arrhythmia or 
myocarditis. Acute kidney injury was defined as a 50% increase in the baseline creatinine level or a creatinine 
level greater than 1.5 mg/dl if the previous value was unknown.
Immunocompromised patients included those with solid organ, hematopoietic stem cell transplantation, 
glucocorticoid treatment (equivalent dose of prednisone ≥ 15 mg/day) or immunosuppressive drugs. Patients 
with HIV were reported in a separate group. Reasons for readmission, including respiratory symptoms, venous 
or arterial thrombosis, exacerbation of chronic diseases, organ failure, and bacterial infection were registered. 
Information on readmissions and death after admission was collected by retrospective review of the clinical 
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history and by telephone contact with the patient and family members one month after discharge. Telephone 
tracking was not possible in 294 patients, which accounted for 4% of the patients discharged.
Data analysis. Participants’ demographic, clinical, epidemiological, laboratory, and diagnostic imaging 
data during the first and second hospital admissions obtained from the Registry data base were analyzed. Treat-
ment received, complications, and clinical progress were also examined. Quantitative variables are expressed as 
median [interquartile range] or median [SD]. Categorical variables are expressed as absolute frequencies and 
percentages. The chi-square test and Fisher’s exact test were used to compare categorical variables while Student’s 
t-test and the Mann–Whitney U Test were used to compare continuous variables. Univariate and multivariate 
logistic regression models were created using Stata 14.0 software (Stata Corp., College Station, USA). All tests 
of significance were two-tailed and p values < 0.05 were considered statistically significant. A logistic regression 
was performed by grouping common variables with a p value < 0.1 and clinical relevance and a number of miss-
ings < 10%.
Ethical aspects. Personal data is processed in strict compliance with Spanish Law 14/2007, of July 3, on 
Biomedical Research; Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 
on the protection of natural persons with regard to the processing of personal data and on the free movement 
of such data, and repealing Directive 95/46/EC (General Data Protection Regulation); and Spanish Organic 
Law 3/2018, of December 5, on the Protection of Personal Data and the Guarantee of Digital Rights. The SEMI-
COVID-19 Registry has been approved by the Provincial Research Ethics Committee of Málaga (Spain). We 
attempted to obtain informed consent from all patients. When this was not possible due to biosafety issues, 
informed consent was requested verbally and noted in the medical record. The STROBE statement guidelines 
were followed in the conduct and reporting of this study. The information contained in the database may be 
accessible after contacting the corresponding author and after its reasoned justification.
Results
Over the course of the study period, 8678 patients were included in the registry. Of them, 7137 patients (82.2%) 
were discharged alive. In the following days, 298 patients (4.2%) were readmitted. The median time from dis-
charge to readmission was 7 days (IQR 3–15). 1541 patients (17.7%) died during the index admission and 35 
died during hospital readmission (11.7%, p = 0.007) (Fig. 1). Of the 6839 patients who were discharged alive and 
were not readmitted, 50 died during the first month after discharge (0.73%). Among the patients who received 
macrolides, azithromycin was the most frequently administered (99.1%).
Clinical characteristics of the patients who are readmitted. Table 1 shows the clinical character-
istic of patients who were readmitted compared to those who were not. The univariate analysis showed that 
readmitted patients were older (74 vs 65 years, p < 0.001) and had more severe comorbidity. The duration of 
symptoms before the index admission was shorter in patients who were subsequently readmitted (p < 0.001). 
A higher percentage of patients who were readmitted had received steroid treatment compared to those who 
were not readmitted (38.3% vs 29.7%, p = 0.002, Table 2). The proportion of patients who received prophylactic 
low-molecular-weight heparin (LMWH) during the primary admission and were readmitted for DVT (87.5%) 
was similar to patients who were readmitted for another reason (86.2%, p = 0.885) and to patients who were not 
readmitted (82.7%, p = 0.645).
Age, Charlson Comorbidity Index score, diabetes, chronic obstructive pulmonary disease (COPD), asthma, 
solid neoplasia, hypertension, dementia, duration of symptoms before admission, hemoglobin level and platelets 
count at admission, ground-glass infiltrate at admission, acute cardiac injury, acute renal failure and steroid treat-
ment during admission were included in the final model (Table 3). Age [odds ratio (OR) per one-year increase: 
1.02; 95% confident interval (95% CI): 1.01–1.03], age-adjusted Charlson comorbidity index score (OR: 1.13; 95% 
CI: 1.06–1.21), COPD (OR: 1.84; 95% CI: 1.26–2.69), asthma (OR: 1.52; 95% CI: 1.04–2.22), hemoglobin level at 
admission (OR: 0.92; 95% CI: 0.86–0.99), ground-glass opacification at admission (OR: 0.86; 95% CI:0.76–0.98) 
and glucocorticoid treatment (OR: 1.29; 95% CI: 1.00–1.66) were independently associated with hospital read-
mission. The C-statistic of the model was 0.661.
The characteristics of patients who were not readmitted versus those who were readmitted because of wors-
ening of SARS-CoV-2 pneumonia are shown in the supplementary material. Most of the variables associated 
with all-cause readmission were also related to readmission for pneumonia (Tables 1, 2, 4 and Table 3S in sup-
plementary material). Patients who were readmitted for pneumonia had a lower prescription of prophylactic 
heparin at discharge. The rate of readmission for pneumonia was lower in patients who had been admitted to 
the ICU during the index admission (2%, 3 patients) than in those who had not been admitted to the ICU (5.7%, 
390 patients; p = 0.041). (Table 3S in supplementary material). The specific multivariate analysis aggregated by 
type of variable is presented in the supplementary material.
Description of the indication for hospital readmission. Table 5 shows the reasons for the readmis-
sion. The most frequent causes were worsening of previous pneumonia (54%), bacterial infection (13%), venous 
thromboembolism (5%), and heart failure (5%). Acute kidney failure, neurological complications, and severe 
hemorrhage were less common as a cause of readmission.
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Discussion
We present the first multicenter study on hospital readmissions of COVID-19 patients carried out in Spain. The 
main finding was that the rate of hospital readmission was relatively low with half of the readmissions occurring 
during the first week after discharge from the hospital. Most of them were due to respiratory worsening. Age, 
comorbidity (especially, asthma and COPD) were associated with an increased risk of readmission. Patients with 
higher hemoglobin levels and ground glass opacification at admission had a lower risk of readmission.
Our readmission rate was similar to those found by other  investigators7,10,12, but lower than those observed 
in other  studies6,9,13,14. The higher readmission rate observed in some studies can be related to the longer follow-
up period in some of  them6,14 and to the higher incidence of diseases such as obesity, hypertension, diabetes, 
asthma and chronic renal  failure6,9,14. On the other hand, we cannot rule out that the severity of infection in the 
patients included in the study was lower than in other series, considering the uncertainties in clinical manage-
ment, which were more prominent during the first wave of the disease. Our results indicate that, after an initial 
clinical improvement, a small but significant number of patients worsen and require readmission to hospital. 
The readmission rate in the present study appears to be lower than that observed in patients admitted for other 
reasons to internal medicine wards in Spain. This observation could be related to the older age and higher 
comorbidity of patients hospitalized for non-COVID-19-related reasons in our  country15.
Although the average hospital occupancy per COVID-19 in Spain was around 10% during the first wave, it 
does not appear that there were many precipitous discharges, in view of the modest rate of  readmissions1,16. The 
criteria usually followed to evaluate hospital discharge in patients with respiratory infection, such as disappear-
ance of fever and improvement of respiratory failure, may be effective parameters for discharge ensuring a low 
readmission rate. We have the impression that the recommendations established in China at the beginning of 
the pandemic could be overly conservative (no fever for 3 days in addition to clinical, analytical, and radiological 
improvement) and could lead to an unnecessary prolongation of the hospital  stay5.
Another characteristic of readmissions is their lower mortality compared to the index  admission6,13. It cannot 
be ruled out that this finding could be influenced by the possible death of the most fragile patients during the 
index admission. The differences detected in the mortality of hospital readmissions in patients with COVID-19 
Figure 1.  Flow chart of inclusion of patients with COVID-19 according to hospital readmission.
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between different hospitals could be justified by the degree of difficulty of admission of non-critical patients, 
which is related to the pressure on the healthcare  system10.
Clinical characteristics of the patients who are readmitted. Older age and comorbidity were asso-
ciated with an increased risk of readmission, as has been reported in previous  studies5,17. Both factors often 
predispose patients to complications that may require  readmission6,7. Not unexpectedly, readmissions for an 
infection that primarily affects the lungs are more frequent in patients with chronic lung disease such as asthma 
or  COPD7,18,19. Adjusting the treatment of chronic lung disease (corticosteroids, bronchodilators or oxygen flow) 
Table 1.  Clinical characteristics of patients with COVID-19 according to hospital readmission. *A patient 
could have several radiological patterns.
Characteristics No readmission n = 6839 Missing Readmission n = 298 Missing p Overall missing
Demographic
Age (median, IQR) 65 (53–75) 4 (0,1%) 74 (60–83) 1 (0,3%)  < 0.001 5 (0.1%)
Obesity (n, %) 1297 (19.0) 640 (9.3%) 70 (23.5) 23 (7.7%) 0.054 663 (9.2%)
Age-adjusted Charlson 
Comorbidity Index (mean, 
SD)
3.0 (2.4) 231 (3.4%) 4.4 (2.7) 9 (3.0%)  < 0.001 240 (3.4%)






Black 36 (0.5) 0 (0.0)
Hispanic 684 (10.0) 29 (9.7)
Asian 41 (0.6) 2 (0.7)
Other 80 (1.3) 1 (0.3)
Unknown 120 (1.8) 7 (2.4)
Comorbidity (n, %)
Hypertension 3081 (45.1) 3 (< 0.1%) 166 (55.7) 0  < 0.001 3 (< 0.1%)
Diabetes 1113 (16.3) 0 64 (21.1) 0 0.029 0
Cardiovascular disease 833 (12.2) 458 (6.7%) 72 (24.2) 19 (6.4%)  < 0.001 477 (6.6%)
Asthma 554 (8.1) 3 (< 0.1%) 37 (12.4) 0 0.008 3 (< 0.1%)
Chronic obstructive pulmo-
nary disease 364 (5.3) 0 42 (14.1) 0  < 0.001 0
Cerebrovascular disease 349 (5.1) 265 (3.9%) 25 (8.4) 5 (1.7%) 0.012 270 (3.8%)
HIV infection 58 (0.8) 30 (0.4%) 1 (0.3) 0 0.341 30 (0.4%)
Solid tumor 467 (6.8) 29 (0.4%) 29 (9.7) 0 0.049 29 (0.4%)
Hematologic malignancies 112 (1.6) 0 5 (1.7) 0 0.645 0
Immunosuppression 225 (3.3) 26 (0.4%) 7 (2.4) 0 0.394 26 (0.4%)
End-stage kidney failure 
(dialysis) 45 (0.7) 52 (0.7%) 6 (2.0) 2 (0.7%) 0.001 54 (0.7%)
Chronic hepatopathy 227 (3.3) 0 17 (5.7) 0 0.029 0
Dementia 427 (6.2) 20 (0.3%) 39 (13.1) 0  < 0.001 20 (0.3%)
Hospital admission characteristics
Acquisition (n,%)
 Community 6469 (94.6) 0 269 (90.3) 0 0.001 0
 Long-term care facility 370 (5.4) 0 29 (9.7) 0 0.001 0
Duration of symptoms 
(median, IQR) 7 (4–10) 84 (1.2%) 5 (3–8) 3 (1.0%)  < 0.001 87 (1.2%)
Length of index hospital stay 9 (6–14) 5 (< 0.1%) 9 (6–15) 0 0.461 5 (< 0.1%)
ICU admission 390 (5.7) 0 12 (4.0) 0 0.219 0
Systolic blood pressure, mm 
Hg (mean, SD) 129.0 (20.3) 356 (5.2%) 131.6 (23.9) 13 (4.4%) 0.038 369 (5.2%)
Diastolic blood pressure, mm 
Hg (mean, SD) 75.0 (12.7) 360 (5.3%) 72.9 (13.6) 15 (5.0%) 0.009 375 (5.2%)
Temperature, °C (mean, SD) 37.1 (1.0) 246 (3.6%) 37.1 (0.9) 8 (2.7%) 0.660 242
Radiological pattern (n,%)*
 Ground-glass opacity 4236 (61.9) 75 (1.1%) 149 (50.0) 5 (1.7%)  < 0.001 80 (1.1%)
 Pleural effusion 218 (3.2) 76 (1.1%) 15 (5.0) 7 (2.3%) 0.086 83 (1.2%)
 Consolidation 3228 (47.2) 87 (1.3%) 112 (37.6) 5 (1.7%) 0.006 92 (1.3%)
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appropriately and determining the frequency of contacts with their physicians could be beneficial. Dementia 
was associated with an increased risk of readmission in the univariate analysis. Interestingly, patients transferred 
to a skilled nursing facility also showed an increased risk of readmission in previous  studies6. The prevention 
and treatment of delirium during admission to reduce the risk of readmission is also one of the aspects to be 
 considered17.
The duration of symptoms in patients who were readmitted (median 5 days) was shorter than in those who 
were not readmitted (IQR) (7 days, < 0.001, Table 2). The prolonged clinical course with frequent worsening that 
Table 2.  Treatment, complications, and progress of patients with COVID-19 depending on hospital 
readmission. LMWH: Low-molecular-weight heparin, ARDS: acute respiratory distress syndrome, MOF: 
multiple organ failure. 198.2% azithromycin, 1.2% other macrolides. *A patient could have several radiological 
patterns.
Treatments No readmission n = 6839 Missing Readmission n = 298 Missing p Overall missing
Duration of invasive ventila-
tion (median, IQR) 10 (7–15) 28 (0.4%) 8 (6–16) 1 (0.3%) 0.966 29 (0.4%)
Duration of noninvasive venti-
lation (median, IQR) 4 (2–8) 32 (0.5%) 4 (3–8) 1 (0.3%) 0.612 33 (0.5%)
Glucocorticoid treatment 
(n, %) 2034 (29.7) 53 (0.8%) 114 (38.3) 1 (0.3%) 0.002 54 (0.8%)
LMWH, prophylactic dose, 
during admission (n,%) 5658 (82.7) 0.9% (65) 246 (82.6) 5 (1.7%) 0.791 70 (0.9%)
Remdesivir (n, %) 31 (0.5) 86 (1.3%) 1 (0.3) 3 (1.0%) 0.611 89 (1.2%)
Interferon (n, %) 784 (11.5) 75 (1.0%) 32 (10.7) 0 0.674 75 (1.0%)
Lopinavir/Ritonavir (n, %) 4533 (66.3) 32 (0.5%) 163 (54.7) 0  < 0.001 32 (0.5%)
Macrolide (n, %)1 4291 (62.7) 44 (0.6%) 153 (51.3) 1 (0.3%)  < 0.001 45 (0.6%)
Hydroxychloroquine (n, %) 6128 (89.6) 22 (0.3%) 257 (86.2) 0 0.075 22 (0.3%)
Chloroquine (n, %) 256 (3.7) 56 (0.8%) 10 (3.4) 1 (0.3%) 0.722 57 (0.8%)
Tocilizumab (n, %) 577 (8.4) 55 (0.8%) 19 (6.4) 0 0.240 55 (0.8%)
Complications (n, %)
Bacterial pneumonia 510 (7.5) 17 (0.2%) 31 (10.4) 0 0.062 17 (0.2%)
ARDS 1481 (21.7) 28 (0.4%) 59 (19.8) 2 (0.7%) 0.435 30 (0.4%)
Acute kidney injury 539 (7.9) 4 (< 0.1%) 40 (13.4) 0  < 0.001 4 (< 0.1%)
Acute cardiac injury 220 (3.2) 17 (0.2%) 39 (13.1) 0  < 0.001 17 (0.2%)
Stroke 21 (0.3) 16 (0.2%) 1 (0.3) 0 1.000 16 (0.2%)
Sepsis 136 (2.0) 4 (< 0.1%) 6 (2.0) 0 1.000 4 (< 0.1%)
Shock 82 (1.2) 39 (0.6%) 5 (1.7) 1 (0.3%) 0.414 40 (0.6%)
MOF 37 (0.5) 21 (0.3%) 4 (1.3) 0  < 0.001 21 (0.3%)
Table 3.  Final multivariate analysis of variables related to risk of readmission in patients with COVID-19. 1 Per 
one-year increase. 2 Acute cardiac injury: acute myocardial infarction, heart failure, arrhythmia or myocarditis.
Variable adjusted OR 95%CI p
Age 1 1.02 1.01–1.03  < 0.001
Age-adjusted Charlson Comorbidity Index score 1.13 1.06–1.21 0.001
Diabetes mellitus 1.05 0.74–1.47 0.796
Chronic obstructive pulmonary disease 1.84 1.26–2.69 0.002
Asthma 1.52 1.04–2.22 0.031
Solid neoplasm 0.70 0.42–1.18 0.186
Hypertension 0.88 0.67–1.16 0.251
Dementia 1.18 0.79–1.77 0.408
Duration of symptoms before admission 1.00 0.99–1.00 0.909
Hemoglobin level at admission 0.92 0.86–0.99 0.028
Platelets count at admission 1.00 1.00–1.00 0.175
Ground-glass opacification at admission 0.86 0.76–0.98 0.026
Acute cardiac  injury2 1.23 0.74–2.00 0.416
Acute kidney failure 1.23 0.85–1.78 0.269
Glucocorticoid treatment 1.29 1.00–1.66 0.049
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characterizes moderate and severe forms of the disease suggests that the time of onset of the patient’s symptoms 
should be taken into account when considering hospital  discharge20,21. A shorter duration of index admission has 
been associated with a higher risk of  readmission6,7; a result that has not been observed in our series. Admission 
to the ICU has also been associated with a lower risk of readmission due to SARS-CoV_2 pneumonia in our 
patients, which may be related to a longer hospital stay of index admission and possible better medical  care6.
Serum hypoalbuminemia at admission has been associated with a worse prognosis including the risk of hos-
pital  readmission22. Yeo et al., observed a direct correlation between the peak creatinine concentration during 
admission and the risk of  readmission10. In our study, acute renal failure was associated with an increased risk 
of readmission but only in the univariate analysis. Hypoalbuminemia and renal dysfunction could be markers 
of more severe disease and multiorgan failure increasing the risk of readmission. The presence of ground-glass 
opacities (GGO) showed to be a protective factor for hospital readmission. This result may be explained by the 
fact that the presence of ground-glass opacities, both in unilateral and bilateral involvement, is associated with 
an early stage of the disease, which could be related to the risk of hospital  readmission23. The efficacy of the 
combination of certain clinical variables and analytical markers in the prediction of hospital readmission could 
be a line of research that could improve our knowledge of the evolution of this  disease16,24.
In our study the association between glucocorticoid treatment and hospital readmission was remarkable. 
Since there was no generalized prescription of corticosteroids during the first wave, we cannot rule out that this 
Table 4.  Analytical results of patients with COVID-19 according to hospital readmission. 1 Sample at 
admission was obtained during the first 24 h of admission. Variables are expressed as median (interquartile 
range).
Cohort n = 6839 Missing Readmission n = 298 Missing p Overall Missing
Sample at admission1
Oxygen saturation, % 94.1 (4.3) 196 (2.9%) 93.9 (4.3) 8 (2.7%) 0.533 204 (2.9%)
Hemoglobin, g/dL 14.0 (1.7) 27 (0.4%) 13.3 (2.0) 0  < 0.001 27 (0.4%)
Platelets ×  106/L 204,993 (87,595.1) 35 (0.5%) 194,500 (79,822.9) 0 0.042 35 (0.5%)
White blood cell count/uL 5950 (4610–7860) 30 (0.4%) 6400 (4600–8400) 0 0.114 30 (0.4%)
Lymphocytes cel/uL 1000 (700–1309) 64 (0.9%) 924 (700–1300) 1 (0.3%) 0.228 53 (0.9%)
Neutrophils cel/uL 4200 (3025–6000) 83 (1.2%) 4600 (3100–6400) 2 (0.7%) 0.102 85 (1.2%)
Neutrophil-to-lymphocyte ratio 4.2 (2.7–7.0) 83 (1.2%) 4.6 (2.9–7.2) 2 (0.7%) 0.116 85 (1.2%)
Eosinophils ×  106/L 0.0 (0.0–20.0) 154 (2.2%) 0.0 (0.0–30.0) 3 (1.0%) 0.322 157 (2.2%)
C-Reactive Protein, mg/L 49.4 (15.7–107.9) 290 (4.2%) 47.5 (15.6–112.2) 8 (2.7%) 0.977 284 (4.2%)
Table 5.  Cause of hospital readmission in 298 patients previously admitted due to COVID-19. 1 Respiratory 
(18 patients), urinary tract (9 patients), intra-abdominal (6 patients), acute gastroenteritis (2 patients), 
Clostridioides difficile colitis (1 patient), surgical wound (1 patient). 2 Five cases due to arrhythmia and one 
case due to acute myocardial infarction. 3 Psychosis (3 patients), acute pancreatitis (3 patients), vasculitis (3), 
diabetes with hyperosmolar state (2 patient), anemia (2 patients), viral syndrome due to Cytomegalovirus (1 
patient), Pneumocystis jirovecii pneumonia, Guillain-Barré polyradiculopathy (1 patient), pneumothorax (1 
patient), generalized seizure (1 patient), adenocarcinoma of the pancreas (1 patient). Seven patients presented 
more than one cause for hospital admission.
Condition Hospital readmission (n = 298)
Pneumonia 158 (53.6)
Bacterial  infection1 38 (12.8)
Venous thromboembolic disease 16 (5.4)
Heart  failure2 16 (5.4)
Acute kidney failure 13 (4.4)
Encephalopathy or delirium 7 (2.3)
Chronic lung disease exacerbation 7 (2.3)
Severe hemorrhage 6 (2)
Home isolation impossibility 5 (1.7)
Generalized exanthema 4 (1.3)
Ischemic stroke 4 (1.3)
Acute hepatitis 4 (1.3)
Bone fracture 4 (1.3)
Social problem 4 (1.3)
Other conditions 3 19 (6.4)
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treatment was a surrogate marker of greater pulmonary involvement predisposing to hospital  readmission25. In 
addition, a positive association was found in the univariant analysis between macrolide treatment and a reduc-
tion in risk of hospital readmission. These results are surprising considering the results of several clinical studies 
that examined the role of azithromycin (administered together with hydroxychloroquine) in the prognosis of 
COVID-19 and found no benefit in terms of mortality or significant clinical  improvement26,27. Macrolide treat-
ment was not included in the multivariate analysis because we are not sure that its association with the risk of 
readmission was due to variables not analyzed.
Description of the cause for admission at initial admission and readmission. As in other similar 
studies, worsening SARS-CoV-2 pneumonia, bacterial infection, venous thromboembolism, heart failure, acute 
renal failure, and neurological or psychiatric conditions were common causes of hospital  readmission5,7,13. The 
administration of more effective and less toxic treatments, determining the dose and rate of decrease of ster-
oids, and the development of prognostic scores could lead to fewer or milder exacerbations of SARS-CoV-2 
 pneumonia28,29.
Bacterial infection was a common cause of readmission. Early removal of invasive devices and close monitor-
ing of infection symptoms are important measures, given the late onset of some nosocomial infections in these 
patients and the masking effect of steroids or interleukin inhibitors on clinical  presentation8,30.
Venous thromboembolism was also a relatively frequent cause of readmission that usually appeared in the 
four weeks following the initial hospital  admission31. This disease is related to coagulopathy, viral endothelial 
damage due to COVID-19, and immobilization during  hospitalization31. Although our study is limited in its 
ability to evaluate this disease, use of LMWH was not associated with a lower risk of readmission due to  DVT32. 
Likewise, there is still a need to better define the risk estimate and the dose and duration of prophylactic LMWH 
in COVID-19  patients31,32.
Worsening of cardiac, digestive, endocrine or urinary diseases due to COVID-19 their sequelae appear to be 
frequent reasons for readmission in our and other  studies6. Therapy during index admission such as the infusion 
of IV fluids, diuretics, nephrotoxic drugs, should be given with great caution, given its possible relationship with 
heart and kidney failure that could precipitate a  readmission33. Preventive strategies according to comorbidity 
of the patient may reduce the risk of organ failure and readmission in covid-19 patients. A close contact with 
the patient, provided with an app., a thermometer and a pulse oximeter, after discharge has resulted in a lower 
risk of  readmission34.
Limitations. Several limitations of the study should be pointed out. First, as a multicenter study, it is likely 
that the discharge criteria at each of the participating hospitals differed, so quite different patients may have been 
analyzed all together. Second, relevant variables such as persistence of fever in the final hours before discharge 
were not collected and as such, we are unable to determine their relationship to readmission risk or compare 
them to other variables. Third, the learning curve for this new disease and changes in the demand for hospital 
admissions during the course of the epidemic may have increased disparity in patient management. Fourth, 
since the patients included in this study corresponded to the months of March and April 2020, the COVID-
19 treatment they received was different from that subsequently recommended. Specifically, there has been a 
decrease in the use of drugs that we now know do not reduce mortality (hydroxychloroquine, azithromycin, 
lopinavir-ritonavir, interferon) and an increase in the use of steroids and interleukin inhibitors. Fifth, another 
limitation is the inability to analyze whether some patients remained hospitalized longer solely due to social 
and epidemiological reasons (i.e. being unable to take precautions to reduce transmission of the infection at 
home). Sixth, since we have not analyzed the number of patients who returned to the emergency department 
with persistent symptoms but were not readmitted during the peak of the pandemic, we must acknowledge some 
uncertainty in the assertion that the reduced proportion of readmissions was due to a favorable clinical outcome. 
Lastly, some variables were missing results for a large number of patients, especially in the case of procalcitonin, 
interleukin-6, D-dimer, lactate dehydrogenase and ferritin. In any case, only variables with a number of failures 
lower than 10% were included in the multivariate analysis. Despite this, we believe that the information obtained 
is useful for the management of patients admitted with COVID-19.
Conclusions
In conclusion, we observed a low readmission rate after discharge from the hospital for COVID-19. Worsening 
of previous pneumonia, bacterial infection, venous thromboembolism, and heart failure were common causes 
of hospital readmission. Advanced age and comorbidity were associated with an increased risk of readmission. 
Our study could help to recognize patients at high risk of readmission, which would allow the establishment of 
strategies during the index admission and after discharge to reduce the frequency of these episodes.
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